Aug 27, 2025

Regina Barzilay

Professor, MIT

Annalisa Merelli

Open follow modal

Personalized Content

Annalisa Merelli

Follow this author to personalize your feed and get instant alerts.

FollowGo to your personalized feed

WHY FOLLOW?

Custom Feed: See the stories that matter most to you.
Smart Alerts: Get notified about major news as it happens.

Update your preferences in Account Settings

Photo-Illustration by TIME (Source Photo: Sophie Park—The Washington Post/Getty Images)

Regina Barzilay is in the business of patient future-telling. That is, using machine learning AI models to predict disease—including when and how it will strike, along with how it may behave. Barzilay began pursuing this after being diagnosed with breast cancer in 2014. As a patient, she experienced the frustrating uncertainty surrounding individual prognoses. Her questions about treatments were often answered in reference to what happened to the participants of clinical trials, but she felt those answers gave her little information about her individual situation.

As an AI researcher, she knew how to address that uncertainty. “To me it was quite clear,” she says, “That's what machine learning is about.” A decade later, the AI model she and her team built, named MIRAI, is able to detect a patient’s risk of developing breast cancer within five years. By 2025, MIRAI was validated by over 2 million mammograms in 48 hospitals across 22 countries.

And her future-telling continues. In 2024, Barzilay worked on an AI model that estimates the expected effectiveness of candidate flu vaccines by predicting which versions of the flu virus are likely to spread next season. She’s now working on using the same concept on cancer, in order to predict how patients—particularly with advanced cancers—will react to a specific treatment. “We are constantly running behind the disease,” she says. “The idea here is to be able to predict it.”